Last reviewed · How we verify

NCT04309643

Drug-drug Interaction Study of CTP-543 and Oral Contraceptives in Healthy Female Subjects

Completed Phase 1 Last updated 16 July 2020
What this trial tests

Phase 1 trial testing CTP-543 in Healthy Volunteers in 21 participants. Completed in 8 July 2020.

Timeline
9 June 2020
Primary endpoint
25 June 2020
8 July 2020

Quick facts

Lead sponsorConcert Pharmaceuticals
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Designsequential
Maskingnone
Primary purposeother
Enrollment21
Start date9 June 2020
Primary completion25 June 2020
Estimated completion8 July 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Concert Pharmaceuticals — full company profile →

Who can join

Adults 18 to 65, female only, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, fixed sequence, multiple dose, open-label study of the effect of CTP-543 on oral contraceptive pharmacokinetics in healthy female subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of CTP-543

Trials testing the same drug.

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

Other Concert Pharmaceuticals trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04309643.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing